New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
06:10 EDTTSROTESARO 3.2M share Secondary priced at $31.50
Citigroup, Deutsche Bank and Leerink acted as joint book running managers for the offering.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
09:20 EDTTSROTESARO management to meet with Leerink
Subscribe for More Information
September 8, 2014
12:22 EDTTSROOPKO reports licensee TESARO submits NDA for Rolapitant
Subscribe for More Information
08:10 EDTTSROTESARO submits rolapitant NDA to FDA
TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use